

eReferences

- e1. Gonzalez NR, Dusick JR, Connolly M, et al. Encephaloduroarteriosynangiosis for adult intracranial arterial steno-occlusive disease: long-term single-center experience with 107 operations. *J Neurosurg* 2015;123:654-661.
- e2. Zhang Q, Li Y, Tong H, et al. Comparison of Therapeutic Efficacy Between Isolated Encephaloduroarteriosynangiosis and Medical Treatment in Patients with Atherosclerotic Middle Cerebral Artery Occlusion. *World Neurosurg* 2018;117:e483-e492.
- e3. Gonzalez NR, Jiang H, Lyden P, et al. Encephaloduroarteriosynangiosis (EDAS) revascularization for symptomatic intracranial atherosclerotic steno-occlusive (ERSIAS) Phase-II objective performance criterion trial. *Int J Stroke* 2020:1747493020967256.
- e4. Wang Y, Chen W, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. *BMJ* 2019;365:l2211.
- e5. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N Engl J Med* 2017;377:1319-1330.
- e6. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. *N Engl J Med* 2009;360:354-362.
- e7. Turan TN, Lynn MJ, Nizam A, et al. Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. *Circ Cardiovasc Qual Outcomes* 2012;5:e51-60.
- e8. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. *Circulation* 2019;140:e673-e691.
- e9. Waters MF, Hoh BL, Lynn MJ, et al. Factors Associated With Recurrent Ischemic Stroke in the Medical Group of the SAMMPRIS Trial. *JAMA Neurol* 2016;73:308-315.
- e10. Choi EH, Lee H, Chung JW, et al. Ring Finger Protein 213 Variant and Plaque Characteristics, Vascular Remodeling, and Hemodynamics in Patients With Intracranial Atherosclerotic Stroke: A High-Resolution Magnetic Resonance Imaging and Hemodynamic Study. *J Am Heart Assoc* 2019;8:e011996.
- e11. Amin-Hanjani S, Pandey DK, Rose-Finnell L, et al. Effect of Hemodynamics on Stroke Risk in Symptomatic Atherosclerotic Vertebrobasilar Occlusive Disease. *JAMA Neurol* 2016;73:178-185.
- e12. Wabnitz AM, Derdeyn CP, Fiorella DJ, et al. Hemodynamic Markers in the Anterior Circulation as Predictors of Recurrent Stroke in Patients With Intracranial Stenosis. *Stroke* 2018:STROKEAHA118020840.
- e13. Liebeskind DS, Cotsonis GA, Saver JL, et al. Collaterals dramatically alter stroke risk in intracranial atherosclerosis. *Ann Neurol* 2011;69:963-974.
- e14. Liebeskind DS, Kosinski AS, Lynn MJ, et al. Noninvasive fractional flow on MRA predicts stroke risk of intracranial stenosis. *J Neuroimaging* 2015;25:87-91.
- e15. Hou C, Duan J, Luo Y, et al. Remote limb ischemic conditioning treatment for intracranial atherosclerotic stenosis patients. *Int J Stroke* 2016;11:831-838.
- e16. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* 2017;377:1119-1131.
- e17. Caso V, Mas JL. Optimization of stroke prevention: colchicine may be an option. *Eur J Neurol* 2020;27:1099.
- e18. Turan TN, Nizam A, Lynn MJ, et al. Relationship between risk factor control and vascular events in the SAMMPRIS trial. *Neurology* 2017;88:379-385.
- e19. Ovbiagele B, Cruz-Flores S, Lynn MJ, Chimowitz MI, Warfarin-Aspirin Symptomatic Intracranial Disease Study G. Early stroke risk after transient ischemic attack among individuals with symptomatic intracranial artery stenosis. *Arch Neurol* 2008;65:733-737.

- e20. Chaturvedi S, Turan TN, Lynn MJ, et al. Do Patient Characteristics Explain the Differences in Outcome Between Medically Treated Patients in SAMMPRIS and WASID? *Stroke* 2015;46:2562-2567.
- e21. Weber R, Kraywinkel K, Diener HC, Weimar C, German Stroke Study C. Symptomatic intracranial atherosclerotic stenoses: prevalence and prognosis in patients with acute cerebral ischemia. *Cerebrovasc Dis* 2010;30:188-193.
- e22. Ovbiagele B, Saver JL, Lynn MJ, Chimowitz M, Group WS. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. *Neurology* 2006;66:1344-1349.
- e23. Turan TN, Maidan L, Cotsonis G, et al. Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. *Stroke* 2009;40:505-509.
- e24. Sangha RS, Naidech AM, Corado C, Ansari SA, Prabhakaran S. Challenges in the Medical Management of Symptomatic Intracranial Stenosis in an Urban Setting. *Stroke* 2017;48:2158-2163.
- e25. Kozak O, Tariq N, Suri MF, Taylor RA, Qureshi AI. High risk of recurrent ischemic events among patients with deferred intracranial angioplasty and stent placement for symptomatic intracranial atherosclerosis. *Neurosurgery* 2011;69:334-342; discussion 342-333.
- e26. Tian L, Yue X, Xi G, et al. Multiple intracranial arterial stenosis influences the long-term prognosis of symptomatic middle cerebral artery occlusion. *BMC Neurol* 2015;15:68.
- e27. Feng X, Chan KL, Lan L, et al. Stroke Mechanisms in Symptomatic Intracranial Atherosclerotic Disease: Classification and Clinical Implications. *Stroke* 2019;50:2692-2699.
- e28. Pawar ST TNL, M. J.; Nizam, A.; Le, N. A.; Montgomery, J.; Derdeyn, C. P.; Fiorella, D.; Lane, B. F.; Janis, S.; Chimowitz, M. I. Association between lipoprotein (A) levels and vascular events in the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) trial. *Stroke* 2014.
- e29. Frankel MRQ AZ, Y.; Long, Q.; Le, N. A.; Waller, E. K.; Lynn, M.; Arenillas, J. F.; Lane, B.; Chimowitz, M. Biomarkers of ischemic outcomes in symptomatic intracranial stenosis (BIOSIS) - Preliminary results. *Stroke* 2014.
- e30. Li J WA, Zhao X, et al. High-sensitive C-reactive protein and dual antiplatelet in intracranial arterial stenosis. *Neurology* 2018;90:e447-e454.
- e31. Candell-Riera J, Arenillas JF, Romero-Farina G, et al. Prognostic value of myocardial perfusion gated SPECT in patients with symptomatic intracranial large-artery atherosclerosis. *Cerebrovasc Dis* 2007;24:247-254.
- e32. Yamauchi H, Higashi T, Kagawa S, et al. Is misery perfusion still a predictor of stroke in symptomatic major cerebral artery disease? *Brain* 2012;135:2515-2526.
- e33. Wang Y, Zhao X, Liu L, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study. *Stroke* 2014;45:663-669.
- e34. Kwon HM, Lynn MJ, Turan TN, et al. Frequency, Risk Factors, and Outcome of Coexistent Small Vessel Disease and Intracranial Arterial Stenosis: Results From the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. *JAMA Neurol* 2016;73:36-42.
- e35. Chen H, Pan Y, Zong L, et al. Cerebral small vessel disease or intracranial large vessel atherosclerosis may carry different risk for future strokes. *Stroke Vasc Neurol* 2020;5:128-137.
- e36. Zhu B, Liu H, Pan Y, et al. Elevated Neutrophil and Presence of Intracranial Artery Stenosis Increase the Risk of Recurrent Stroke. *Stroke* 2018;49:2294-2300.
- e37. Tan TY, Kuo YL, Lin WC, Chen TY. Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis. *J Neurol* 2009;256:187-193.